We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00370201
Recruitment Status : Unknown
Verified March 2004 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Active, not recruiting
First Posted : August 31, 2006
Last Update Posted : October 9, 2006
Information provided by:

Study Description
Brief Summary:
This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment

Condition or disease Intervention/treatment Phase
Rhegmatogenous Retinal Detachment Drug: colchicine Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : March 2004
Estimated Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Colchicine
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. proliferative vitreoretinopathy
  2. retinal reattachment rate

Secondary Outcome Measures :
  1. visual acuity
  2. reoperation
  3. macular pucker

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Rhegmatogenous retinal detachment

Exclusion Criteria:

  • PVR grade C
  • Duration of retinal detachment ≥ one month
  • History of cataract surgery
  • History of RD surgery
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00370201

Iran, Islamic Republic of
Hamid Ahmadieh,MD
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
More Information

ClinicalTrials.gov Identifier: NCT00370201     History of Changes
Other Study ID Numbers: 8259
First Posted: August 31, 2006    Key Record Dates
Last Update Posted: October 9, 2006
Last Verified: March 2004

Keywords provided by Shahid Beheshti University of Medical Sciences:
retinal detachment
proliferative vitreoretinopathy

Additional relevant MeSH terms:
Retinal Detachment
Vitreoretinopathy, Proliferative
Retinal Diseases
Eye Diseases
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents